Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies Academic Article uri icon

Overview

MeSH Major

  • Neoplasms
  • Oligodeoxyribonucleotides

abstract

  • This is the first report of the combined modality treatment using antisense oligonucleotides with radiation therapy in patients with advanced cancer. A dose of 2.0 mg/kg of LErafAON administered twice weekly is tolerated with premedication and does not enhance radiation toxicity in patients. The observation of dose-dependent, infusion-related reactions has led to further modification of the liposomal composition for use in future clinical trials.

publication date

  • February 15, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-05-1260

PubMed ID

  • 16489081

Additional Document Info

start page

  • 1251

end page

  • 9

volume

  • 12

number

  • 4